Aspire Biopharma Holdings (ASBP) Total Current Liabilities (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Total Current Liabilities for 6 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 84.03% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $1.7 million, a 84.03% decrease from a year earlier, with the FY2025 full-year figure at $7.6 million, up 349.79% from the prior year.
• Total Current Liabilities was $1.7 million for Q2 2026 at Aspire Biopharma Holdings, down from $3.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $13.9 million in Q3 2025 and troughed at $51756.0 in Q1 2022.
• A 5-year average of $3.5 million and a median of $1.7 million in 2026 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 2094.53% in 2024 and plunged 84.03% in 2026, its largest moves.
• Over 5 years, Total Current Liabilities stood at $303323.0 in 2022, then soared by 32.97% to $403328.0 in 2023, then surged by 318.54% to $1.7 million in 2024, then soared by 349.79% to $7.6 million in 2025, then slumped by 77.79% to $1.7 million in 2026.
• The last three Total Current Liabilities figures came in at $1.7 million (Q2 2026), $3.2 million (Q1 2026), and $7.6 million (Q4 2025), per Business Quant data.